Centessa Pharmaceuticals (CNTA) Equity Average (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Equity Average data on file, last reported at $507.1 million in Q1 2026.

• Quarterly Equity Average rose 28.74% year-over-year to $507.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.1 million (up 28.74% YoY) and the FY2025 annual result came in at $464.2 million, up 45.57% from the prior year.
• Equity Average grew to $507.1 million in Q1 2026 per CNTA's latest filing, from $414.2 million in the prior quarter.
• Across five years, Equity Average topped out at $507.1 million in Q1 2026 and bottomed at $225.7 million in Q1 2024.
• The 5-year median for Equity Average is $365.6 million (2025), against an average of $360.4 million.
• The widest annual swing landed in 2022, when Equity Average soared 279.26%; it then plunged 36.69% in 2023.
• Tracing CNTA's Equity Average over 5 years: stood at $354.5 million in 2022, then tumbled by 30.1% to $247.8 million in 2023, then surged by 81.72% to $450.3 million in 2024, then dropped by 8.02% to $414.2 million in 2025, then increased by 22.42% to $507.1 million in 2026.
• Per Business Quant, the three latest CNTA Equity Average figures stand at $507.1 million (Q1 2026), $414.2 million (Q4 2025), and $323.2 million (Q3 2025).

Peer Comparison